rs4696480 — TLR2 T-16934A

TLR2 T-16934A — Turning Up the Volume on Innate Immune Signaling

Your immune system maintains a constant conversation with the microbial world — sensing bacteria, fungi, and other pathogens through a set of molecular detectors called pattern recognition receptors¹¹ pattern recognition receptors
PRRs — the first-responder surveillance system of innate immunity, active before the adaptive immune response can mount a targeted attack. Toll-Like Receptor 2 (TLR2) is one of the most promiscuous of these sensors, recognizing an unusually broad array of microbial signals including bacterial lipoproteins, peptidoglycan from gram-positive cell walls, lipoteichoic acid, mycobacterial components, and fungal zymosan. The T-16934A variant (rs4696480) sits in the TLR2 promoter region — not in the coding sequence, but in the regulatory stretch of DNA that governs how much TLR2 the body produces. Carriers of the A allele appear to have altered TLR2 transcriptional output, and the consequences of this expression shift ripple through several inflammatory conditions.

The A allele at rs4696480 is remarkably common — approximately 50% frequency in Europeans, 58% in East Asians, and 38% in Africans. This means the AA genotype is present in roughly 20% of the global population, making it one of the most prevalent functional variants in the entire TLR family.

The Mechanism

At position -16934 in the TLR2 promoter, the T-to-A substitution alters the local DNA sequence recognized by transcription factors that bind this regulatory region. This is an intronic/upstream regulatory variant²² intronic/upstream regulatory variant
classified as an intron variant on dbSNP, located within TLR2 genomic sequence at chr4:153,685,974 on GRCh38 that likely affects transcription factor binding affinity and chromatin accessibility at the TLR2 locus.

Unlike the nearby missense variant R753Q (rs5743708), which produces a structurally impaired TLR2 protein, T-16934A operates at the transcriptional level — modulating how much functional TLR2 protein is synthesized. The AA genotype is associated with increased TLR2-mediated inflammatory responses in the context of skin and respiratory disease, consistent with upregulated receptor expression. A neonatal cord blood study found that AA genotype carriers born to atopic mothers show significantly increased FOXP3, GITR, and LAG3 expression in regulatory T cells³³ significantly increased FOXP3, GITR, and LAG3 expression in regulatory T cells
along with elevated Th2 cytokines and TNF-α secretion when stimulated — suggesting altered immune programming from birth in genetically susceptible individuals. This early-life immune skewing may set the trajectory for later atopic disease.

The Evidence

Atopic dermatitis is the condition most extensively studied in relation to rs4696480. A Ukrainian pediatric cohort of 103 atopic dermatitis patients and 84 healthy controls found the AA genotype associated with severe AD phenotype⁴⁴ AA genotype associated with severe AD phenotype
OR 6.395 (95% CI 1.240–32.991) — a striking effect size from a relatively small study, indicating the AA genotype substantially increases risk of severe rather than mild disease. This severity association, rather than simply disease presence, mirrors what was found for the coding variant R753Q in earlier work. A systematic review and meta-analysis⁵⁵ systematic review and meta-analysis
confirming significant association across allelic, homozygous, heterozygous, and dominant models of inheritance confirmed the overall association between rs4696480 and atopic dermatitis.

Psoriasis shows a similar pattern. A Turkish case-control study of 140 psoriasis patients and 250 controls found the AA genotype associated with elevated psoriasis risk⁶⁶ AA genotype associated with elevated psoriasis risk
adjusted OR 2.41 (95% CI 1.349–4.292), p=0.003 — robust after covariate adjustment. The involvement of TLR2 in psoriasis is biologically coherent: keratinocytes express TLR2, and its signaling contributes to the IL-17/IL-23 axis that drives psoriatic plaques.

Asthma susceptibility is also elevated. A meta-analysis of 13 studies⁷⁷ meta-analysis of 13 studies
finding OR 2.455 (95% CI 1.235–4.88) under the dominant model — meaning AA+AT carriers have roughly 2.5-fold higher asthma risk than TT homozygotes found significant association between rs4696480 and asthma susceptibility, making it the only TLR2 variant among rs4696480, rs5743708, rs3804099, and rs3804100 to show this association. This implicates airway TLR2 activity in asthma pathogenesis — possibly through enhanced responses to microbial triggers that promote type 2 inflammation in susceptible airways.

Skin tumors associated with HPV are also linked to this variant. A Croatian case-control study of 161 keratoacanthoma cases, 152 common wart cases, and 469 controls found TLR2 rs4696480 A allele and AA genotype significantly overrepresented⁸⁸ TLR2 rs4696480 A allele and AA genotype significantly overrepresented
P<0.001 — with stronger association in common warts, which are caused by HPV, suggesting TLR2 expression level affects antiviral innate responses in skin.

Inflammatory bowel disease susceptibility is also modulated by this variant. A Danish cohort of 624 Crohn's disease patients, 411 ulcerative colitis patients, and 795 controls found rs4696480 associated with IBD risk in combined patient analysis⁹⁹ associated with IBD risk in combined patient analysis
alongside other inflammatory pathway polymorphisms in TLR4, TLR9, TNFRSF1A, IL6R, IL10, IL23R, and PTPN22, consistent with TLR2's role in mucosal immune surveillance of gut bacteria.

Epistatic interactions add another layer of complexity. A study examining interactions between FCER1A (the high-affinity IgE receptor alpha chain) and TLR2 found that TT homozygotes carrying the FCER1A rs2252226 minor allele had higher SCORAD than all other combined genotype groups¹⁰¹⁰ TT homozygotes carrying the FCER1A rs2252226 minor allele had higher SCORAD than all other combined genotype groups
demonstrating that TLR2 expression level interacts with IgE receptor genetics to modify atopic dermatitis severity in a non-additive fashion. This epistatic finding shows that the "normal" TT genotype at rs4696480 is not uniformly protective — its effect depends on co-occurring immune receptor variants.

Practical Implications

The T-16934A variant affects the gain, not the function, of TLR2 signaling. Unlike R753Q (which produces a broken receptor), the A allele at rs4696480 may produce more TLR2, creating a system that amplifies inflammatory responses to microbial ligands. This creates a somewhat paradoxical pattern: higher TLR2 expression can drive more intense inflammatory skin responses (atopic dermatitis, psoriasis) while also potentially affecting mucosal immune homeostasis in the gut.

For AA genotype carriers, the actionable implications center on inflammatory skin conditions and atopic disease management. The variant does not impair pathogen recognition — the TLR2 receptors produced are functional, just potentially more numerous — so infection susceptibility differs fundamentally from the pattern seen with R753Q. The clinical priority is managing the downstream consequences of enhanced TLR2 activity: atopic inflammation, skin barrier integrity, and monitoring for inflammatory conditions in which TLR2 overactivation plays a role.

Interactions

Within the TLR2 locus itself, rs4696480 and rs5743708 (R753Q) have been studied together in several atopic dermatitis investigations. These two variants operate through opposite mechanisms — T-16934A modulates expression, R753Q impairs function — yet both associate with severe AD. Carrying both a promoter upregulation variant and a loss-of-function coding variant in the same gene creates a complex phenotype where TLR2 may be abundantly present but functionally impaired, potentially confounding the downstream inflammatory pattern.

The TLR2/FCER1A epistatic interaction (rs4696480 × rs2252226) documented in atopic dermatitis suggests that TLR2 expression level modulates the IgE-mediated arm of allergic inflammation, connecting innate pattern recognition to the adaptive allergic response. This cross-pathway interaction implies that carriers of both variants warrant heightened atopic monitoring.

For gut mucosal immunity, TLR2 operates alongside TLR4 (rs4986790) and CD14 in recognizing the microbial content of the intestinal lumen. Enhanced TLR2 expression from the A allele, combined with other inflammatory pathway variants in NOD2 or IL23R, could amplify mucosal inflammatory responses relevant to IBD phenotype and severity.